Pharmaceutical Ananda Developments today announced that investee company Israel-Cannabis (iCAN) has signed a memorandum of understanding (MoU) with a new Israeli medical cannabis company, Yom Chai, to develop and clinically validate cannabis-based treatments for Crohn's disease, autism and other neurodevelopmental, neurodegenerative and gastrointestinal diseases. 21 August 2018